Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04171726

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04171726
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04171726. Allocation not applicable; no masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2023-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
Acronym
REDOX-TAVI
Condition
Aortic Valve Stenosis
Intervention (Drug)
Edoxaban
Lead sponsor
Erasmus Medical Center (class: other)
Collaborator
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct04171726
Content hash
a3d4825ba31bdcd9a4ac4819fb3bbebcd0007e81eeb5abf7decc074540c907fa